Eisai appalled, others unsurprised by Germany price snub for antiepileptic
This article was originally published in Scrip
Executive Summary
The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system in Germany, has said it considers any additional benefit of Eisai's antiepileptic drug, Fycompa (perampanel) over two other comparator treatments (lamotrigine or topiramate) as "unproven" – a ruling that has "appalled" the company.